1% v/wt), stored under MAP)) and MER2 [(EDTA, oregano oil (0.3% v/wt), stored under MAP)]. Quality evaluation of product stored under APR-246 mouse above packaging conditions and treated with EDTA and oregano oil was conducted using microbiological, chemical and sensory analyses. Based on mesophilic total viable counts (TVC) a microbiological shelf-life extension of 7, 9, 15 or >15 days was obtained for M, ME, MER1 or MER2 liver samples, respectively, compared to the control’s (A) shelf-life of 3 days. Air-packaged liver samples showed higher pH values
in the first 8 days of storage compared to M, ME, MER1 and MER2 samples, with the latter showing a significant decrease at the end of the storage period. Interestingly, the presence of the oregano oil in MER1 and MER2 liver resulted in a lower production of TBA compared to all other samples. Based on sensory analysis, MER1 and MER2 extended the shelf-life of chicken liver by 14-15
days, while treatments M and ME by 7 and 9 days, respectively. Our results support the hypothesis that the shelf-life of chicken liver meat may substantially be extended GNS-1480 cell line (by almost 3 times the usual product’s shelf-life using a natural antimicrobial combination (EDTA, oregano oil and MAP). (C) 2011 Elsevier Ltd. All rights reserved.”
“PURPOSE: A universal loss of von Willebrand factor (vWF) high-molecular-weight multimers (HMWM) has been demonstrated in continuous-flow left ventricular assist device (HeartMate II) recipients. However, no reliable clinical or laboratory predictors for an increased bleeding tendency in this patient population have been identified. This study evaluated the ability of a new automated latex particle-enhanced immunoturbidimetric vWF activity assay (ALPEIVA) to predict non-surgical
bleeding risk in HeartMate II recipients.
METHODS: CH5424802 Protein Tyrosine Kinase inhibitor As part of a prospective multicenter trial, pre-surgical, 7-day, and 30-day post-implantation blood samples were collected from 24 patients. ALPEIVA-assessed vWF activities were compared among patients with and without non-surgical bleeding complications after HeartMate II implantation. Additional laboratory testing included factor VIII activity (FVIII:C), vWF antigen (vWFAg), vWF ristocetin cofactor activity (vWF:RCo), and vWF multimer analysis.
RESULTS: All 24 patients had HMWM losses after HeartMate II implantation. Five patients (20%) developed non-surgical bleeding complications between 14 days and 6 months after HeartMate II implantation. Among various laboratory variables, only mean ALPEIVA/vWFAg ratios (referred to as the “”bleeding ratio”") were significantly lower in patients with clinically relevant bleeding (mean, 0.70 +/- 0.06) compared with patients without bleeding (mean, 0.78 +/- 0.09; p = 0.02) when measured at 30 days.